Lewis K, Maio M, Demidov L, et al. BRIM8: a randomized, double-blind, placebo-controlled study of adjuvant vemurafenib in patients (pts) with completely resected, BRAFV600+ melanoma. ESMO 2017, abstract LBA7_PR.
Encorafenib en binimetinib bij niet-resectabel of gemetastaseerd BRAF-gemuteerd melanoom
apr 2019 | Dermato-oncologie